WO2020176461A3 - Methods and compositions for treating neuroendocrine prostate cancer - Google Patents

Methods and compositions for treating neuroendocrine prostate cancer Download PDF

Info

Publication number
WO2020176461A3
WO2020176461A3 PCT/US2020/019631 US2020019631W WO2020176461A3 WO 2020176461 A3 WO2020176461 A3 WO 2020176461A3 US 2020019631 W US2020019631 W US 2020019631W WO 2020176461 A3 WO2020176461 A3 WO 2020176461A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
prostate cancer
compositions
nepc
neuroendocrine prostate
Prior art date
Application number
PCT/US2020/019631
Other languages
French (fr)
Other versions
WO2020176461A2 (en
Inventor
Miguel REINA-CAMPOS
Jorge Moscat
Maria T. Diaz-Meco
Original Assignee
Sanford Burnham Prebys Medical Discovery Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanford Burnham Prebys Medical Discovery Institute filed Critical Sanford Burnham Prebys Medical Discovery Institute
Publication of WO2020176461A2 publication Critical patent/WO2020176461A2/en
Publication of WO2020176461A3 publication Critical patent/WO2020176461A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides

Abstract

Disclosed herein are methods for identifying a subject as having or developing a subset of a disease or condition, including but not limited to the subset of prostate cancer known as neuroendocrine prostate cancer (NEPC), and models of human NEPC. Also provided herein are methods for treating NEPC in the subject and methods for preventing the onset of NEPC in a subject suffering from prostate cancer.
PCT/US2020/019631 2019-02-25 2020-02-25 Methods and compositions for treating neuroendocrine prostate cancer WO2020176461A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962810296P 2019-02-25 2019-02-25
US62/810,296 2019-02-25

Publications (2)

Publication Number Publication Date
WO2020176461A2 WO2020176461A2 (en) 2020-09-03
WO2020176461A3 true WO2020176461A3 (en) 2020-12-10

Family

ID=72239904

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2020/019631 WO2020176461A2 (en) 2019-02-25 2020-02-25 Methods and compositions for treating neuroendocrine prostate cancer

Country Status (1)

Country Link
WO (1) WO2020176461A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116144769B (en) * 2022-09-09 2023-09-01 广州医科大学附属第一医院（广州呼吸中心） sgRNA primer based on PCA3 and PSA double genes, detection reagent and application thereof
CN116286654B (en) * 2023-02-28 2024-01-30 创芯国际生物科技(广州)有限公司 Prostate cancer organoid, culture medium and culture method

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040224919A1 (en) * 2001-02-21 2004-11-11 Joseph Rubinfeld Restoring cancer-suppressing functions to neoplastic cells through DNA hypomethylation
WO2014025046A1 (en) * 2012-08-09 2014-02-13 独立行政法人国立がん研究センター Promoter of differentiation from hepatic progenitor cell into hepatic cell, and use thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040224919A1 (en) * 2001-02-21 2004-11-11 Joseph Rubinfeld Restoring cancer-suppressing functions to neoplastic cells through DNA hypomethylation
WO2014025046A1 (en) * 2012-08-09 2014-02-13 独立行政法人国立がん研究センター Promoter of differentiation from hepatic progenitor cell into hepatic cell, and use thereof

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
CHANG, YT ET AL.: "REST is a crucial regulator for acquiring EMT-like and stemness phenotypes in hormone-refractory prostate cancer", SCIENTIFIC REPORTS, vol. 7, no. 42795, 3 March 2017 (2017-03-03), XP055764311, DOI: 10.1038/srep42795 *
FIELDS, AP ET AL.: "Protein kinase C [iota]: human oncogene , prognostic marker and therapeutic target", PHARMACOLOGICAL RESEARCH, vol. 55, no. 6, June 2007 (2007-06-01), pages 487 - 497, XP022127335, DOI: 10.1016/j.phrs. 2007.04.01 5 *
JIA, XQ ET AL.: "Increased Expression of PHGDH and Prognostic Significance in Colorectal Cancer", TRANSLATIONAL ONCOLOGY, vol. 9, no. 3, 1 June 2016 (2016-06-01), pages 191 - 196, XP055764308, DOI: 10.1016/j.tranon. 2016.03.00 6 *
LIU, C ET AL. ET AL.: "Activating Transcription Factor 4 Promotes Angiogenesis of Breast Cancer through Enhanced Macrophage Recruitment", BIOMED RESEARCH INTERNATIONAL, vol. 2015, 974615, 25 March 2015 (2015-03-25), pages 1 - 8, XP055764307, DOI: 10.1155/2015/974615 *
PAUL, A ET AL.: "PKCλ/ι signaling promotes triple-negative breast cancer growth and metastasis", CELL DEATH AND DIFFERENTIATION, vol. 21, no. 9, 2 May 2014 (2014-05-02), pages 1469 - 1481, XP055764312, DOI: 10.1038/cdd.2014.62 *
REINA-CAMPOS, M ET AL.: "Increased Serine and One Carbon Pathway Metabolism by PKC [lambda]/[iota] Deficiency Promotes Neuroendocrine Prostate Cancer", CANCER CELL, vol. 35, no. 3, 28 February 2019 (2019-02-28), pages 385 - 400.e9, XP085638419, DOI: 10.1016/j.ccell. 2019.01.01 8 *
RIAZ, N ET AL.: "Expression of Androgen Receptor and Cancer Stem Cell Markers ( CD 44 +/ CD 24- and ALDH1+): Prognostic Implications in Invasive Breast Cancer", TRANSLATIONAL ONCOLOGY, vol. 11, no. 4, August 2018 (2018-08-01), pages 920 - 929, XP055764316, DOI: 10.1016/j.tranon. 2018.05.00 2 *
SOUNDARARAJAN, R ET AL.: "Function of Tumor Suppressors in Resistance to Antiandrogen Therapy and Luminal Epithelial Plasticity of Aggressive Variant Neuroendocrine Prostate Cancers", FRONTIERS IN ONCOLOGY, vol. 8, 15 March 2018 (2018-03-15), pages 1 - 5, XP055764315, DOI: 10.3389/fonc.2018.00069 *
STUCHBERY, R ET AL.: "Reduction in expression of the benign AR transcriptome is a hallmark of localised prostate cancer progression", ONCOTARGET, vol. 7, no. 21, 24 May 2016 (2016-05-24), pages 31384 - 31392, XP055764310, DOI: 10.18632/oncotarget.8915 *
ZHANG, T ET AL.: "Meta-analysis of the prognostic value of p-4EBP1 in human Malignancies", ONCOTARGET, vol. 9, no. 2, 7 December 2017 (2017-12-07), pages 2761 - 2769, XP055764309, DOI: 10.18632/oncotarget.23031 *

Also Published As

Publication number Publication date
WO2020176461A2 (en) 2020-09-03

Similar Documents

Publication Publication Date Title
AU2017225061B2 (en) Biomarkers and methods of treating PD-1 and PD-L1 related conditions
PH12019501116A1 (en) Compounds with anti-tumor activity against cancer cells bearing egfr or her2 exon 20
MX2020012028A (en) Methods and compositions for treating cancer.
MX2021001857A (en) Diagnostic and therapeutic methods for the treatment of breast cancer.
EA201000016A1 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER, TUMORS AND DISTURBANCES ASSOCIATED WITH TUMORS
MX2019010848A (en) Compositions and methods for treating cancer.
TW200621240A (en) Cancer treatments
TW200806322A (en) Diagnostics and treatments for tumors
RS20150135A1 (en) Treatment with anti-vegf antibodies
MX2021005075A (en) Methods for treating castration-resistant and castration- sensitive prostate cancer.
ATE510553T1 (en) BETA-2-GLYCOPROTEIN 1 AS ANGIOGENESIS INHIBITOR
MX2009006779A (en) Vegf-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors.
PH12020551043A1 (en) Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues
MX2022010425A (en) Methods of treating estrogen receptor-associated diseases.
CR20220626A (en) 4-oxo-3,4-dihydroquinazolinon compounds for the treatment of braf-associated diseases and disorders
MX2019004969A (en) Selective inhibitor of exon 20 insertion mutant egfr.
MX2022002244A (en) Method for identifying responders to smarca2/4 degraders.
MX2020012613A (en) Compositions and uses thereof for treating disease or condition.
WO2020176461A3 (en) Methods and compositions for treating neuroendocrine prostate cancer
MX2019012176A (en) Chk1 (sra737)/parpi combination methods of inhibiting tumor growth.
MX2023000191A (en) Methods of making and using pde9 inhibitors.
MX2022002682A (en) Anti-cd73 antibodies.
AU2018271862A1 (en) Combination therapy
WO2018064013A8 (en) METHODS FOR TREATING CANCER WITH BAVITUXIMAB BASED ON LEVELS OF β2-GLYCOPROTEIN 1, AND ASSAYS THEREFOR
PH12021551047A1 (en) Anti-ptk7 immune cell cancer therapy

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20763121

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20763121

Country of ref document: EP

Kind code of ref document: A2